Umbilical Cord Blood (UCB) Allogeneic Stem Cell Transplant for Hematologic Malignancies.

Trial Profile

Umbilical Cord Blood (UCB) Allogeneic Stem Cell Transplant for Hematologic Malignancies.

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Dec 2015

At a glance

  • Drugs Antithymocyte globulin (Primary) ; Ciclosporin (Primary) ; Mycophenolate mofetil (Primary) ; Mycophenolate mofetil (Primary) ; Busulfan; Cyclophosphamide; Methylprednisolone
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Chronic myelomonocytic leukaemia; Graft-versus-host disease; Lymphoid leukaemia; Lymphoproliferative disorders; Myelodysplastic syndromes; Myelofibrosis; Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Dec 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
    • 12 Apr 2015 Planned primary completion date changed from 1 Mar 2014 to 1 Sep 2015 as per ClinicalTrials.gov record.
    • 28 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top